Automate Your Wheel Strategy on STXS
With Tiblio's Option Bot, you can configure your own wheel strategy including STXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol STXS
- Rev/Share 0.3134
- Book/Share 0.0932
- PB 67.3508
- Debt/Equity 2.0375
- CurrentRatio 1.0695
- ROIC -1.1704
- MktCap 190061989.0
- FreeCF/Share -0.0907
- PFCF -23.8651
- PE -7.5548
- Debt/Assets 0.1284
- DivYield 0
- ROE -2.1713
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments.
Read More
Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year's Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot's revolutionary clinical capabilities and “weekend” installation.
Read More
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
Published: March 07, 2025 by: Seeking Alpha
Sentiment: Positive
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep will generate significant recurring revenue per procedure and expand the advantages of using robotics in EP.
Read More
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.
Read More
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Read More
Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in TD Cowen's 45th Annual Healthcare Conference in Boston, Massachusetts.
Read More
About Stereotaxis, Inc. (STXS)
- IPO Date 2004-08-12
- Website https://www.stereotaxis.com
- Industry Medical - Instruments & Supplies
- CEO David Leo Fischel C.A.I.A.,
- Employees 139